Exenatide
Shop Exenatide
Shop ExenatideCode ths10 applied at checkout
By The Health Stacks Research TeamUpdated September 20, 2026
Exenatide is a man-made copy of a natural body chemical called GLP-1. This chemical is made in the gut after you eat. It helps the body release insulin, which lowers blood sugar. Exenatide is a medicine used by adults with type 2 diabetes.
Doctors can give it as a shot twice a day, or as a longer-acting shot once a week. This medicine helps lower blood sugar after meals. It does this by copying the gut chemical that tells the pancreas to make more insulin when blood sugar is high. Studies also suggest it may help with weight loss and may protect the heart.
Newer research hints it might even help people with asthma or lung problems have fewer flare-ups. Most side effects are stomach problems like nausea, vomiting, and diarrhea. There is a warning that it may raise the chance of pancreatitis, which is a painful swelling of the pancreas. When it is taken with other diabetes medicines like sulfonylureas, blood sugar can drop too low. People should always use this medicine under a doctor's care.
ApprovedApproved by a regulator (e.g. FDA) for a specific medical use — the highest research-status tier. Verified confidence80–100 — backed by strong, well-corroborated sources (peer-reviewed research, clinical guidelines). Our highest confidence tier.
Benefits
What Exenatide Helps With
The benefits people report — backed by research.
Glycemic & metabolic (31)
Treatment of Type 2 Diabetes 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcInsulin sensitivity 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Suppression of glucagon secretion 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Angiogenesis 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →GLP-1 RAs decrease blood glucose and glycated hemoglobin 92/100Rated 92/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improved glycemic control in T2DM 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improved glucose concentrations and HbA1c 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Rescues beta-cell replication and survival following calcineurin inhibition 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Delayed onset of diabetes 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Enhanced beta-cell mass 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improved glucose tolerance 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduction in insulitis scores 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improves beta cell function and survival during ER stress 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Absence of severe hypoglycemia compared with some antidiabetics 88/100Rated 88/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Prevention of renal complications of type 2 diabetes 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Sustains beta-cell survival in experimental diabetes 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Suppresses abnormal postprandial hyperglucagonemia and hyperglycemia 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →No significant increase in risk of NAION, glaucoma, or retinopathy vs other antidiabetic treatments 82/100Rated 82/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Potential for beta-cell regeneration 75/100Rated 75/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Induces Glut-4 translocation to the plasma membrane 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →GLP-1 receptor agonism 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →GIP receptor agonism 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Exenatide derived from Gila monster venom 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →GLP-1 receptor agonists approved for Type 2 diabetes 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improved glucose control and reduced HbA1c 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Increased beta-cell mass via stimulation of beta-cell replication and neogenesis 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Prevention or delay of diabetes development in neonatal models 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improves glycemic control and reduces HbA1c in Type 2 Diabetes 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Superior glycemic control compared to twice-daily exenatide 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Significant reduction in fasting plasma glucose 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improved beta cell function estimated by HOMA 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →
Gastrointestinal & gut (6)
Gastric / gut lining 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Lack of drug-induced pancreatic safety signals 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Attenuates chemically induced pancreatitis 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Does not alter basal plasma amylase or lipase in non-pancreatitis models 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →No adverse effects on pancreatic exocrine structure and function 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Increases cholangiocyte growth in vitro and in vivo 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →
Cardiovascular & vascular (6)
Angiogenesis 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcIncreased atrial contractility 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduced risk of composite all-cause death or hospitalization for heart failure 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduced first plus recurrent hospitalization for heart failure events 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduces systolic blood pressure 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reductions in systolic blood pressure 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →
Weight management (4)
Weight management 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Exenatide attenuated ventral striatum/septal fMRI response to alcohol cues, with reduced heavy drinking in patients with obesity 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Brain / cognitive 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Exenatide attenuated ventral striatum response to alcohol cues on fMRI in AUD patients, with reduced heavy drinking in those with obesity 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →
Cytoprotection / cellular defense (2)
Reduced incidence of all-cause death 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Enhances translational expression of ATF4, a transcription factor central for stress remedy and cell survival 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →
Neuroprotection & cognitive (2)
Induces neuroendocrine transdifferentiation of pancreatic ductal cells 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Brain / cognitive 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →
Musculoskeletal (2)
Angiogenesis 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Muscle recovery 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →
More reported benefits (12)
Exenatide infusion reduced mean pulmonary artery pressure in idiopathic PAH and CTEPH patients 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Exenatide infusion reduced mean pulmonary artery pressure in PAH patients 88/100Rated 88/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →In MCT PAH rats, exenatide improved RV stroke-volume, RV ejection fraction, and RV-arterial coupling 88/100Rated 88/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →In MCT rats, exenatide improved RV stroke-volume, RV ejection fraction, and RV-arterial coupling 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Pharmacologic RARα inhibition with AR7 restored GLS1 expression and protected against aortic dissection in mice 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Treatment of Idiopathic Intracranial Hypertension 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Exenatide is a synthetic version of exendin-4, a 39-amino acid peptide isolated from Gila monster saliva 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Exenatide showed potential benefit in Parkinson's disease models 60/100Rated 60/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improved animal survival and physical condition 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →PCPE-1 depletion ameliorated LV fibrosis and diastolic dysfunction in obese and aged HFpEF mouse models 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Liver health 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Insulin sensitivity 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →
Free: The Peptide Stack Cheat-Sheet
You just read the research on Exenatide. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.
No spam. Unsubscribe anytime.
How People Use It
1 reported routine — each line links to the source it came from.
From published sources
Routines as reported in peer-reviewed papers, clinical guidance, or vetted media — each linked to the source it came from.
SubQ
- Subcutaneous injection; oral formulation available for semaglutide since 2020 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources17Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source
mg vs mcg: one milligram (mg) equals 1,000 micrograms (mcg) — multiply by 1,000 going from mg to mcg, divide by 1,000 going from mcg to mg. Mixing the two up is a thousand-fold dosing error: 1 mg taken instead of 1 mcg is a 1,000× overdose; 1 mcg instead of 1 mg is a 1,000× underdose. Always double-check the unit label and the decimal place.
Safety
Known Side Effects
Adverse effects reported in the research and by community use.
- Minimal-to-moderate islet hypertrophyModerate 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ncbi.nlm.nih.gov
- Slightly higher total amylase concentrationsMild 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ncbi.nlm.nih.gov
- Decreased food intakeMild 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ncbi.nlm.nih.gov
- Adverse effects of Hypoglycemic Agents/Peptides/VenomsMild 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ncbi.nlm.nih.gov
- NauseaMildReported in 10 sources 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources10Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ doi.org↗ doi.org↗ singlecare.com↗ peptidedeck.com+6
- VomitingMildReported in 10 sources 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources10Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ doi.org↗ doi.org↗ singlecare.com↗ peptidedeck.com+6
- DiarrheaMildReported in 6 sources 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources6Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ doi.org↗ doi.org↗ peptidedeck.com↗ glucagon.com+2
- Injection-site reactionsMildReported in 2 sources 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ doi.org↗ diabetes.co.uk
- HeadacheMildReported in 3 sources 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ doi.org↗ singlecare.com↗ diabetes.co.uk
- Reduction in CD4+CD25+Foxp3+ regulatory T cells in the thymusModerate 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ ncbi.nlm.nih.gov
- Upset stomachMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
- Diarrhea or constipationMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
- Hypoglycemia (low blood sugar)ModerateReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com↗ ro.co
- Feeling jitteryMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
- DizzinessMildReported in 3 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com↗ glucagon.com↗ diabetes.co.uk
- WeaknessMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
- Decreased appetiteMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
- Risk of thyroid C-cell tumorsSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ singlecare.com
- Gastrointestinal events and disordersModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ nature.com
- Increased side effects (associated with retatrutide)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ drugdiscoverytrends.com
- Immune reaction with neutralizing antibodies; immune-mediated serious bleeding (exenatide)Severe 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ webmd.com
- Reduction in body weightMild 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- PancreatitisSevereReported in 2 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com↗ peptideguide.com
- HeadachesMildReported in 2 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com↗ diabetes.co.uk
- Increased heart rateMildReported in 2 sources 60/100Rated 60/100Source typeSpecialist communityIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com↗ glucagon.com
- Injection site nodules / reactionsModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
- Elevated pancreatic amylase and lipaseModerate 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ glucagon.com
Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.
Get Exenatide
Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.
Shop Exenatide
Code ths10 applied at checkout
Evidence
Research Citations (23)
Every claim above traces back to a source you can check — here are 23 of them.
- Source
Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study.
2012 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population.
2012 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects.
2012 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Effects of a new sustained-release microsphere formulation of exenatide, DA-3091, on obese and non-alcoholic fatty liver disease mice.
2013 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males.
2016 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance.
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes.
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Exenatide.
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
A Pilot Study of Exenatide Actions in Alzheimer's Disease.
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Exenatide can reduce glucose independent of islet hormones or gastric emptying.
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome.
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Endothelial dysfunction induced by triglycerides is not restored by exenatide in rat conduit arteries ex vivo.
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology → - Source
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
News
Latest on Exenatide
Dated, sourced reporting that mentions Exenatide.
ResearchSep 14, 2026
Semaglutide linked to fewer exacerbations in asthma, COPD
An abstract presented at the 2026 European Respiratory Society International Congress links semaglutide use in patients with type 2 diabetes to fewer exacerbations in asthma (38% reduction) and COPD (21% reduction). Other GLP-1 receptor agonists like exenatide and dulaglutide also showed exacerbation reductions. The associations persisted regardless of weight or glycemic changes, suggesting possible direct lung anti-inflammatory effects.
50/100Rated 50/100Source typeUnclassified sourceIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Read →
SafetyAug 13, 2025
Gastrointestinal adverse events associated with GLP-1 RA in non-diabetic patients with overweight or obesity: a systematic review and network meta-analysis
A systematic review and network meta-analysis of 39 studies (33,354 participants) assessed gastrointestinal adverse events of GLP-1 receptor agonists in non-diabetic patients with overweight or obesity. Nausea, vomiting, diarrhea, and constipation were the most common side effects. Orforglipron showed the highest nausea risk, followed by exenatide, tirzepatide, semaglutide, and liraglutide. The differing safety profiles can help clinicians tailor weight-loss therapy choices.
72/100Rated 72/100Source typeEstablished referenceIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Read →
Regulatory
Novo Nordisk Receives FDA Approval of OZEMPIC® (semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes
The FDA has approved Novo Nordisk's once-weekly GLP-1 receptor agonist Ozempic (semaglutide) to improve glycemic control in adults with type 2 diabetes. Based on the SUSTAIN Phase 3a clinical trial program involving over 8,000 adults, the drug demonstrated superior A1c reductions compared to sitagliptin and exenatide extended-release, as well as significant weight loss as a secondary benefit. The drug will be available in 0.5 mg and 1 mg pre-filled pen doses.
60/100Rated 60/100Source typeSpecialist communityIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Read →
Wondering how Exenatide pricing compares across suppliers? Our original market data shows the full picture.
See the State of the Peptide Market 2026 →Related on The Health Stacks
Explore by goal
Related peptides